The fast track designation is supported by preclinical evidence of antitumor activity by ADCE-D01 in several STS tumor models ...

Japan's Sosei Group Corp said on Monday it is allying with a U.S. biotech run by former Novartis AG executives to commercialise a neurological drug pipeline.

Funded entirely by taxpayer dollars, this first-of-its-kind drug targets cellular metabolism to promote tissue repair of multiple organs.

Boehringer Ingelheim’s Jascayd (nerandomalist) has got the US Food and Drug Administration (FDA) nod in idiopathic pulmonary fibrosis (IPF), making it the first drug to be approved in this indication ...

(Reuters) -An agreement was reached on all the provisions and implementation mechanisms of the first phase of the Gaza ceasefire agreement, which will lead to ending the war, the release of Israeli ...

DM1 cohort recruitment completion in Q4 2025, topline data in mid-2026, and potential BLA filing for z-basivarsen in late ...

The FDA approved Boehringer's nerandomilast, now Jascayd, as the first new U.S. treatment for idiopathic pulmonary fibrosis ...

Pfizer has re-entered the obesity drug sector by acquiring Metsera, Inc., having successfully outmaneuvered six other bidders ...